Synapse Open Synapse
Biology

Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

BioPharma Dive · · 3 min read

The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

Latest from BioPharma Dive